Harrow (NASDAQ:HROW) Price Target Raised to $70.00 at HC Wainwright

Harrow (NASDAQ:HROW) had its target price upped by HC Wainwright from $69.00 to $70.00 in a research note issued to investors on Wednesday morning, MarketBeat Ratings reports. The brokerage currently has a buy rating on the stock.

Several other equities research analysts also recently weighed in on HROW. Cantor Fitzgerald reissued an “overweight” rating and set a $94.00 price target on shares of Harrow in a research report on Tuesday, November 11th. Zacks Research lowered Harrow from a “strong-buy” rating to a “hold” rating in a report on Monday, February 2nd. LADENBURG THALM/SH SH boosted their price target on Harrow from $64.00 to $66.00 and gave the stock a “buy” rating in a research note on Wednesday, November 12th. William Blair reaffirmed an “outperform” rating on shares of Harrow in a research report on Tuesday. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a report on Thursday, January 22nd. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $71.14.

Harrow Price Performance

HROW opened at $39.22 on Wednesday. The firm has a market cap of $1.46 billion, a PE ratio of -230.69 and a beta of 0.05. The stock has a 50-day moving average price of $48.19 and a 200-day moving average price of $43.76. Harrow has a 1 year low of $20.85 and a 1 year high of $54.85. The company has a debt-to-equity ratio of 4.67, a current ratio of 2.20 and a quick ratio of 2.52.

Harrow (NASDAQ:HROW) last released its quarterly earnings data on Monday, March 2nd. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.23). The firm had revenue of $89.09 million for the quarter, compared to the consensus estimate of $88.42 million. Harrow had a negative net margin of 1.89% and a positive return on equity of 36.51%. Sell-side analysts predict that Harrow will post -0.53 earnings per share for the current fiscal year.

Institutional Trading of Harrow

Several large investors have recently modified their holdings of the company. Larson Financial Group LLC lifted its holdings in Harrow by 13.1% in the fourth quarter. Larson Financial Group LLC now owns 2,446 shares of the company’s stock valued at $120,000 after acquiring an additional 284 shares during the period. Teacher Retirement System of Texas increased its position in shares of Harrow by 4.1% during the 2nd quarter. Teacher Retirement System of Texas now owns 8,478 shares of the company’s stock valued at $259,000 after purchasing an additional 332 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Harrow by 2.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 16,547 shares of the company’s stock valued at $505,000 after purchasing an additional 341 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Harrow by 25.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,800 shares of the company’s stock worth $88,000 after purchasing an additional 369 shares during the period. Finally, Captrust Financial Advisors boosted its holdings in shares of Harrow by 0.5% in the fourth quarter. Captrust Financial Advisors now owns 69,959 shares of the company’s stock worth $3,428,000 after buying an additional 376 shares during the last quarter. Institutional investors own 72.76% of the company’s stock.

Key Stories Impacting Harrow

Here are the key news stories impacting Harrow this week:

• Positive Sentiment: Company reported record 2025 results and issued 2026 outlook, highlighting strong FY25 revenue growth and momentum across key product lines. This underpins the long?term thesis despite mixed near?term guidance. Harrow Health Posts Record 2025 Results, Sets 2026 Outlook
• Positive Sentiment: FDA cleared an IND to start a Phase?3 trial for TRIESENCE to expand the label to ocular inflammation/pain after cataract surgery — a material clinical/catalyst event that can add future revenue and de?risk a higher?margin product line. Harrow to Initiate Phase 3 Clinical Trial
• Positive Sentiment: Analyst support remains: H.C. Wainwright raised its PT to $70 (buy) and Cantor Fitzgerald kept an overweight rating while modestly trimming a PT to $91 — both imply sizable upside versus the current price and likely contributed to buying interest. H.C. Wainwright PT Raised to $70 Cantor Fitzgerald PT Note
• Neutral Sentiment: Management will present at the Leerink Partner’s 2026 Global Healthcare Conference on March 10 — a visibility event that could move the stock depending on messaging but is routine. Harrow to Present at Leerink
• Negative Sentiment: FY?2026 revenue guidance was updated to $350M–$365M, materially below the consensus (~$394M) — this guidance gap is the principal driver of the post?earnings sell?off and investor concern about near?term growth. Harrow outlines $350M–$365M 2026 revenue goal
• Negative Sentiment: Q4 results showed a revenue beat but an EPS miss (reported $0.17 vs. $0.40 expected); margin pressure, rising interest costs and a higher debt load raised concerns in some analyst writeups and led to at least one downgrade. Post?earnings criticism and downgrade
• Negative Sentiment: Critical commentary (rating downgrade) highlighted reliance on costly sales & marketing, acquisitions, and one?time customer stocking in FY25 — factors that could compress near?term margins and cash flow. Analyst critique on margins and leverage

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.